TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Sponsor: Inhibrx Biosciences, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 340 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT04198766 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04198766 Rescue Dossier →